| Governance, performance objectives and organizational form: evidence from hospitals L Eldenburg, BE Hermalin, MS Weisbach, M Wosinska Journal of Corporate Finance 10 (4), 527-548, 2004 | 248 | 2004 |
| Economic and technological drivers of generic sterile injectable drug shortages J Woodcock, M Wosinska Clinical Pharmacology & Therapeutics 93 (2), 170-176, 2013 | 225 | 2013 |
| Direct-to-consumer advertising and drug therapy compliance M Wosinska Journal of Marketing Research 42 (3), 323-332, 2005 | 166 | 2005 |
| Just what the patient ordered? Direct-to-consumer advertising and the demand for pharmaceutical products M Wosinska Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products …, 2002 | 130 | 2002 |
| Understanding firm, physician and consumer choice behavior in the pharmaceutical industry P Manchanda, DR Wittink, A Ching, P Cleanthous, M Ding, XJ Dong, ... Marketing Letters 16, 293-308, 2005 | 111 | 2005 |
| Hospital governance, performance objectives, and organizational form L Eldenburg, B Hermalin, MS Weisbach, M Wosinska National Bureau of Economic Research, 2001 | 37 | 2001 |
| Generic Dispensing And Substitution In Mail And Retail Pharmacies: An in-depth look at some of the market dynamics of pharmacy benefit managers. M Wosinska, RS Huckman Health affairs 23 (Suppl1), W4-409-W4-416, 2004 | 31 | 2004 |
| EFFECTIVENESS OF THE CALIFORNIA R&D TAX CREDIT BH Hall, M WOSINSKA | 24 | 1999 |
| Promoting to multiple agents: the case of direct-to-consumer drug advertising M Wosinska manuscript Harvard Business School. PARIS CLEANTHOUS WELFARE IMPLICATIONS OF …, 2002 | 22 | 2002 |
| The California R&D tax credit: Description, history, and economic analysis BH Hall, M Wosinska California Council on Science and Technology Series, 1999 | 12 | 1999 |
| Federal policies to address persistent generic drug shortages ME Wosińska, RG Frank The Hamilton Project, 2023 | 8 | 2023 |
| Advertising and optimal consumption path: The case of prescription drugs M Wosinska Available at SSRN 459100, 2003 | 8 | 2003 |
| Patient access in restrictive risk management programs: the case of iPLEDGE KW Kerr, ME Wosinska Therapeutic innovation & regulatory science 51 (1), 16-23, 2017 | 7 | 2017 |
| Hospital Governance, Performance Objectives, and Organization Form L Eldenburg, B Hermalin, M Weisbach, M Wosinska Working Paper, University of Arizona, 1999 | 7 | 1999 |
| Direct-to-consumer advertising and patient therapy compliance M Wosinska Unpublished manuscript, 2004 | 6 | 2004 |
| Are shortages going down or not? Interpreting data from the FDA and the University of Utah Drug Information Service ME Wosińska, ER Fox, V Jensen Health Affairs Forefront, 2015 | 5 | 2015 |
| Pharmaceutical Pricing SH Kina, M Wosinska Handbook of Pricing Research in Marketing, 488-511, 2009 | 5 | 2009 |
| A framework for prioritizing pharmaceutical supply chain interventions ME Wosińska, TJ Mattingly II, RM Conti Health Affairs Forefront, 2023 | 4 | 2023 |
| The economics of prescription drug advertising ME Wosinska University of California, Berkeley, 2002 | 4 | 2002 |
| Effects of Direct-to-Consumer Drug Advertising on Prescription Choice M Wosińska Dept. of Economics, University of California at Berkeley, 2001 | 4 | 2001 |
Benjamin HermalinUniversity of CaliforniaVerified email at berkeley.edu
